Meeting
2016 ASCO Annual Meeting
Tumor- and class-specific patterns of immune-related adverse events (irAEs) of immune checkpoint inhibitors (ICIs): A systematic review (SR).
Authors
Daphne Day
Princess Margaret Cancer Centre, Toronto, ON, Canada
Daphne Day , Leila Khoja , Tom Wei-Wu Chen , Lillian L. Siu , Aaron Richard Hansen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Immune Checkpoint Inhibitors
Citation
J Clin Oncol 34, 2016 (suppl; abstr 3065)
DOI
10.1200/JCO.2016.34.15_suppl.3065
Abstract #
3065
Poster Bd #
387
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
eVOLVE-Lung02: A phase 3 study of first-line (1L) volrustomig plus chemotherapy (CT) versus pembrolizumab plus CT in metastatic non-small-cell lung cancer (mNSCLC) with PD-L1 tumor cell (TC) expression <50%.
First Author: Melissa Lynne Johnson
Poster
2024 ASCO Genitourinary Cancers Symposium
Preclinical testing of a novel PD-L1 inhibitor for the treatment of renal cell carcinoma.
First Author: Michelle Hsu
Poster
2024 ASCO Genitourinary Cancers Symposium
Infusion-related reactions with immune checkpoint inhibitors in genitourinary cancers: A systematic review and meta-analysis.
First Author: Yu Fujiwara
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Role of proton pump inhibitors in immune checkpoint inhibitor colitis.
First Author: Roshini Pradeep